TransCode Therapeutics Inc. (NASDAQ:RNAZ – Get Free Report) was down 2.4% during mid-day trading on Monday . The company traded as low as $1.65 and last traded at $1.65. Approximately 20,405 shares changed hands during trading, a decline of 76% from the average daily volume of 85,972 shares. The stock had previously closed at $1.69.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, TransCode Therapeutics has a consensus rating of “Sell”.
View Our Latest Stock Report on RNAZ
TransCode Therapeutics Price Performance
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($7.17) earnings per share (EPS) for the quarter.
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.
Further Reading
- Five stocks we like better than TransCode Therapeutics
- 5 Buy-and-Hold Stocks Built to Weather a Volatile Market
- Movado’s Turnaround Gains Momentum
- Qualcomm’s Discount Could Vanish If Its AI Bet Pays Off
- Micron’s AI Memory Boom Could Send Shares 100% Higher
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
